Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study Salvatore D'Angelo 1,2 * , Fabrizio Cantini 3 , Roberta Ramonda 4 , Luca Cantarini 5 , Antonio Carletto 6 , Maria Sole Chimenti 7 , Andrea Delle Sedie 8 , Rosario Foti 9 , Roberto Gerli 10 , Claudia Lomater 11 , Ennio Lubrano 12 , Antonio Marchesoni 13 , Alen Zabotti 14 , Carlo Salvarani 15,16 , Rossana Scrivo 17 , Raffaele Scarpa 18 , Giuseppina Tramontano 1 , Carlotta Nannini 3 , Mariagrazia Lorenzin 4 , Marta Fabbroni 5 , Federica Martinis 6 , Roberto Perricone 7 , Linda Carli 8 , Elisa Visalli 9 , Guido Rovera 11 , Fabio Massimo Perrotta 12 , Luca Quartuccio 14 , Alessio Altobelli 17 , Luisa Costa 18 , Laura Niccoli 3 , Augusta Ortolan 4 and Francesco Caso 18 1 Rheumatology Department of Lucania, Rheumatology Institute of Lucania (IReL), Potenza, Italy, 2 Basilicata Ricerca Biomedica (BRB), Potenza, Italy, 3 Department of Rheumatology, Hospital of Prato, Prato, Italy, 4 Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Padova, Italy, 5 Research Center of Systemic Autoinflammatory Diseases, Behçet's Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, 6 Rheumatology Unit, University of Verona, Verona, Italy, 7 Rheumatology, Allergology and Clinical Immunology, Department of Medicina dei Sistemi, University of Rome Tor Vergata, Rome, Italy, 8 Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 9 Rheumatology Unit, Vittorio-Emanuele University Hospital of Catania, Catania, Italy, 10 Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, 11 Rheumatology Unit, Ospedale Mauriziano, Torino, Italy, 12 Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute, Università degli studi del Molise, Campobasso, Italy, 13 Department of Rheumatology, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milan, Italy, 14 Rheumatology Clinic, Department of Medical Area, University of Udine, Academic Hospital S. Maria della Misericordia, Udine, Italy, 15 Rheumatology Unit, Deptartment of Internal Medicine, Azienda USL-IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, 16 University of Modena and Reggio Emilia, Modena, Italy, 17 Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, Rome, Italy, 18 Rheumatology Unit, Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA). Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated. Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate. Results: From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ± Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1497 1 Edited by: Daniel Merk, Goethe University Frankfurt, Germany Reviewed by: Simona Gabriela Bungau, University of Oradea, Romania Antonio Recchiuti, Università degli Studi G. d'Annunzio Chieti e Pescara, Italy Karin van Schie, Leiden University Medical Center, Netherlands *Correspondence: Salvatore D'Angelo saldangelo@katamail.com Specialty section: This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology Received: 07 August 2019 Accepted: 19 November 2019 Published: 13 December 2019 Citation: D'Angelo S, Cantini F, Ramonda R, Cantarini L, Carletto A, Chimenti MS, Delle Sedie A, Foti R, Gerli R, Lomater C, Lubrano E, Marchesoni A, Zabotti A, Salvarani C, Scrivo R, Scarpa R, Tramontano G, Nannini C, Lorenzin M, Fabbroni M, Martinis F, Perricone R, Carli L, Visalli E, Rovera G, Perrotta FM, Quartuccio L, Altobelli A, Costa L, Niccoli L, Ortolan A and Caso F (2019) Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Front. Pharmacol. 10:1497. doi: 10.3389/fphar.2019.01497 BRIEF RESEARCH REPORT published: 13 December 2019 doi: 10.3389/fphar.2019.01497